Pfizer And Neurocrine End Partnership

Pfizer Inc. (PFE) will terminate its partnership with Neurocrine Biosciences Inc. (NBIX) to develop the insomnia drug Indiplon because of delays in the approval process. Shares of Neurocrine plummeted $3.96 to close at $9.85 while Pfizer stock eased a penny to close at $22.64.